Kymera Therapeutics

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and favorable safety profile. HS and AD patient cohort data expected in 2H22 INDs cleared and Phase